Last reviewed · How we verify
SSGJ-705 combined with chemotherapy
SSGJ-705 combined with chemotherapy is a Small molecule drug developed by Shenyang Sunshine Pharmaceutical Co., LTD.. It is currently in Phase 2 development.
At a glance
| Generic name | SSGJ-705 combined with chemotherapy |
|---|---|
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSGJ-705 combined with chemotherapy CI brief — competitive landscape report
- SSGJ-705 combined with chemotherapy updates RSS · CI watch RSS
- Shenyang Sunshine Pharmaceutical Co., LTD. portfolio CI
Frequently asked questions about SSGJ-705 combined with chemotherapy
What is SSGJ-705 combined with chemotherapy?
SSGJ-705 combined with chemotherapy is a Small molecule drug developed by Shenyang Sunshine Pharmaceutical Co., LTD..
Who makes SSGJ-705 combined with chemotherapy?
SSGJ-705 combined with chemotherapy is developed by Shenyang Sunshine Pharmaceutical Co., LTD. (see full Shenyang Sunshine Pharmaceutical Co., LTD. pipeline at /company/shenyang-sunshine-pharmaceutical-co-ltd).
What development phase is SSGJ-705 combined with chemotherapy in?
SSGJ-705 combined with chemotherapy is in Phase 2.